Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727833 | 0.79 | IDO1 (0.43) | IDO1NOS1MAPTALDH1A1MEP1A | |
| SCHEMBL4725738 | 0.79 | IDO1 (0.49) | IDO1 | |
| SCHEMBL4729480 | 0.77 | IDO1 (0.41) | IDO1ALDH1A1 | |
| SCHEMBL4725112 | 0.73 | ALDH1A1 (0.51) | IDO1MEN1GAAMAPTKMT2A | |
| SCHEMBL4725111 | 0.73 | ALDH1A1 (0.51) | IDO1MEN1GAAMAPTKMT2A | |
| SCHEMBL4980796 | 0.72 | IDO1 (0.57) | IDO1MAPTHTT | |
| SCHEMBL2520953 | 0.72 | IDO1 (0.70) | IDO1MAPTHTT | |
| SCHEMBL4726890 | 0.70 | IDO1 (0.58) | IDO1MEN1GAAMAPTKMT2A | |
| SCHEMBL4782177 | 0.70 | ALDH1A1 (0.41) | IDO1GAAMAPTHTTALDH1A1 | |
| SCHEMBL21799345 | 0.68 | PRSS1 (0.54) | NOS3NOS1KMT2AALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008036652-A2 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885NOS3 111/4885NOS1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.